Ceftazidime/Avibactam Pfizer

Menu

Close

HomeAboutAbout Ceftazidime/avibactam PfizerPatient ProfilesIDSA guidelinesEfficacySafetyImportant Safety InformationSafety DataDosingMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
IDSA Guidelines

Background

CRE and P. aeruginosa

KPC and OXA-48

Ceftazidime/Avibactam Pfizer is recommended by the IDSA guidance as a preferred treatment option for MDR Gram-negative infections caused by CRE and DTR P. aeruginosa*1
  • Ceftazidime/Avibactam Pfizer has in vitro activity against pathogens producing AmpC, KPC and OXA-48 enzymes2
  • Ceftazidime/Avibactam Pfizer's range of in vitro activity against β-lactamases does not necessarily predict clinical success
  • Ceftazidime/Avibactam Pfizer has no in vitro activity against pathogens producing class B metallo-β-lactamases and is not able to inhibit many class D enzymes2
IDSA has published expert guidance on the treatment of MDR Gram-negative pathogens1

  • These 3 groups of MDR Gram-negative bacteria are considered to pose particular therapeutic challenges1
  • ​​​​​​​These 3 groups have been identified by the CDC as urgent or serious threats3
  • CRE and DTR P. aeruginosa have been identified by the WHO as critical priorities4​​​​​​​
*Defined as P. aeruginosa exhibiting non-susceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam,  meropenem, imipenem-cilastatin, ciprofloxacin and levofloxacin.2

 CDC: Centers for Disease Control and Prevention; CRE: carbapenem-resistant Enterobacterales; DTR: difficult-to-treat resistance; ESBL: extended-spectrum beta-lactamase; IDSA: Infectious Disease Society of America; MDR: multidrug resistant; KPC: Klebsiella pneumoniae carbapenemase; OXA: oxacillinase; WHO: World Health Organization.References: 1. Tamma PD, et al. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. 2020. Infectious Diseases Society of America. Accessed August 2, 2021. https://www.idsociety.org/practice-guideline/amr-guidance. 2. Ceftazidime/Avibactam Pfizer, Summary of product characteristics, Saudi Arabia, February 2021. 3. Antibiotic resistance threats in the United States. 2019. CDC. Accessed August 2, 2021. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. 4. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. WHO. Accessed August 2, 2021. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.
Explore more
Patient Profiles Learn MoreLoading
CRECeftazidime/Avibactam Pfizer is recommended by the IDSA guidance as a preferred treatment option for MDR Gram-negative infections caused by CRE*1Ceftazidime/Avibactam Pfizer is recommended by the IDSA guidance as an alternative treatment option for uncomplicated cystitis caused by CRE.||Pseudomonas aeruginosaCeftazidime/Avibactam Pfizer​​​​​​​ is recommended by the IDSA guidance as a preferred treatment option for MDR Gram-negative infections caused by DTR P. aeruginosa¶1
*For infections outside the urinary tract, resistant to both ertapenem and meropenem, and carbapenemase testing results are either not available or negative.
†Defined as a UTI occurring in association with a structural or functional abnormality of the genitourinary tract, or any UTI in a male patient.
‡Meropenem-vaborbactam, imipenem-cilastatin-relebactam and cefiderocol are also preferred treatment options.
§Meropenem-vaborbactam and imipenem-cilastatin-relebactam are also preferred treatment options.
||Meropenem-vaborbactam, imipenem-cilastatin-relebactam and cefiderocol are also alternative treatment options.
¶Defined as P. aeruginosa exhibiting non-susceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin and levofloxacin.
#Ceftolozane-tazobactam, imipenem-relebactam, cefiderocol and a single dose of an aminoglycoside are also preferred treatment options.
**Ceftolozane-tazobactam, imipenem-cilastatin-relebactam and cefiderocol are also preferred treatment options.
†† Ceftolozane-tazobactam and imipenem-cilastatin-relebactam are also preferred treatment options.CRE: carbapenem-resistant Enterobacterales; DTR: difficult-to-treat resistance; IDSA: Infectious Disease Society of America; MDR: multidrug resistant; KPC: Klebsiella pneumoniae carbapenemase; OXA: oxacillinase; UTI: urinary tract infection.Reference: 1. Tamma PD, et al. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. 2020. Infectious Diseases Society of America. Accessed August 2, 2021. https://www.idsociety.org/practice-guideline/amr-guidance.
Explore more
Patient Profiles Learn MoreLoading
KPC and OXA-48​​​​​​​Ceftazidime/Avibactam Pfizer is recommended By the IDSA guidance as a preferred treatment option for KPC-producing*† and OXA-48-producing CRE infections1The IDSA guidance recommends Ceftazidime/Avibactam Pfizer as the only preferred treatment option for OXA-48-producing CRE infections.1
*KPC identified (or carbapenemase positive but identity of carbapenemase unknown).
†Meropenem-vaborbactam and imipenem-cilastatin-relebactam are also preferred treatment options.CRE: carbapenem-resistant Enterobacterales; IDSA: Infectious Disease Society of America; KPC: Klebsiella pneumoniae carbapenemase; OXA: oxacillinase.Reference: 1. Tamma PD, et al. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. 2020. Infectious Diseases Society of America. Accessed August 2, 2021. https://www.idsociety.org/practice-guideline/amr-guidance.
Explore more
Patient Profiles Learn MoreLoading
About Ceftazidime/Avibactam Pfizer Learn MoreLoading
Limited Treatment Options Learn MoreLoading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.